BB
INCY icon

BB Biotech’s Incyte INCY Stock Holding History

BB Biotech’s Portfolio INCY Stock Details INCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$311M Sell
3,620,000
-188,322
-5% -$15.3M 7.83% 2
2018
Q4 		$242M Hold
3,808,322
– – 7.76% 2
2018
Q3 		$263M Buy
3,808,322
+50,000
+1% +$3.43M 6.96% 5
2018
Q2 		$252M Buy
3,758,322
+60,000
+2% +$4.1M 7.27% 4
2018
Q1 		$308M Hold
3,698,322
– – 8.52% 2
2017
Q4 		$350M Buy
3,698,322
+30,000
+0.8% +$3.14M 9.86% 3
2017
Q3 		$428M Buy
3,668,322
+153,500
+4% +$19.4M 11.85% 2
2017
Q2 		$443M Buy
3,514,822
+25,000
+0.7% +$3.18M 13.53% 1
2017
Q1 		$466M Sell
3,489,822
-390,000
-10% -$49.7M 15.26% 1
2016
Q4 		$389M Hold
3,879,822
– – 14.41% 2
2016
Q3 		$366M Buy
3,879,822
+39,416
+1% +$3.32M 12.86% 1
2016
Q2 		$307M Hold
3,840,406
– – 12.12% 2
2016
Q1 		$278M Buy
3,840,406
+90,000
+2% +$6.71M 11.06% 2
2015
Q4 		$407M Hold
3,750,406
– – 11.46% 2
2015
Q3 		$414M Buy
3,750,406
+10,000
+0.3% +$1.12M 13.12% 1
2015
Q2 		$390M Sell
3,740,406
-51,461
-1% -$5.33M 10.57% 2
2015
Q1 		$348M Sell
3,791,867
-260,000
-6% -$21.5M 10.35% 3
2014
Q4 		$296M Sell
4,051,867
-250,000
-6% -$16.3M 9.59% 3
2014
Q3 		$211M Buy
4,301,867
+138,077
+3% +$6.92M 8.58% 4
2014
Q2 		$235M Buy
4,163,790
+30,000
+0.7% +$1.53M 11.17% 3
2014
Q1 		$221M Sell
4,133,790
-87,297
-2% -$5.42M 11.4% 4
2013
Q4 		$214M Sell
4,221,087
-542,183
-11% -$23.6M 11.42% 4
2013
Q3 		$182M Sell
4,763,270
-593,879
-11% -$17.5M 9.89% 4
2013
Q2 		$118M Buy
+5,357,149
New +$117M 8.49% 4

Other funds holding INCY

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BB Biotech's INCY Position: Q1 2019 in Review

BB Biotech reduced its Incyte (INCY) stake by 4.9% in Q1 2019, selling an estimated $15.3M and leaving 3,620,000 shares worth $311M. The position accounts for 7.83% of the portfolio, ranked #2.

BB Biotech first reported a position in INCY in Q2 2013 and has held it in 24 quarters since. The position peaked at $466M in Q1 2017. 519 funds tracked by Wall St. Rank hold INCY as of Q1 2019.

  • BB Biotech held 3,620,000 shares of Incyte worth $311M as of Q1 2019.
  • BB Biotech sold 188,322 Incyte shares in Q1 2019, an estimated $15.3M.
  • Incyte made up 7.83% of BB Biotech's portfolio in Q1 2019, its #2 holding.
  • BB Biotech first reported a position in Incyte in Q2 2013 and has held it in 24 quarters since.
  • BB Biotech's Incyte position peaked at $466M in Q1 2017.
  • 519 funds tracked by Wall St. Rank held Incyte as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.